Abstract
Neuronal degeneration is closely associated with cognitive, motor and visual dysfunctions. Neuroprotective strategies have been investigated with the view to being employed as potential therapy for patients with these disabilities. Pigment epithelium-derived factor (PEDF) is a 50-kDa secreted glycoprotein and a non-inhibitory member of the serine protease inhibitor (SERPIN) gene family. PEDF is detected in a broad range of human tissues, including almost all brain areas, and has been shown to have strong neuroprotective properties for various types of neurons including cerebellar granule neurons, hippocampal neurons, striatal neurons, retinal neurons and spinal cord motor neurons. These observations raise the possibility that application of PEDF may be helpful in designing new therapeutic strategies for neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinsons disease, Huntingtons disease, Alzheimers disease and brain ischemia.
Keywords: Pigment epithelium-derived factor, neuroprotection, CNS neurons, neurodegenerative disease, ischemia, NF-κB, apoptosis inducing factor
Current Molecular Medicine
Title: The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Volume: 10 Issue: 3
Author(s): T. Yabe, T. Sanagi and H. Yamada
Affiliation:
Keywords: Pigment epithelium-derived factor, neuroprotection, CNS neurons, neurodegenerative disease, ischemia, NF-κB, apoptosis inducing factor
Abstract: Neuronal degeneration is closely associated with cognitive, motor and visual dysfunctions. Neuroprotective strategies have been investigated with the view to being employed as potential therapy for patients with these disabilities. Pigment epithelium-derived factor (PEDF) is a 50-kDa secreted glycoprotein and a non-inhibitory member of the serine protease inhibitor (SERPIN) gene family. PEDF is detected in a broad range of human tissues, including almost all brain areas, and has been shown to have strong neuroprotective properties for various types of neurons including cerebellar granule neurons, hippocampal neurons, striatal neurons, retinal neurons and spinal cord motor neurons. These observations raise the possibility that application of PEDF may be helpful in designing new therapeutic strategies for neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinsons disease, Huntingtons disease, Alzheimers disease and brain ischemia.
Export Options
About this article
Cite this article as:
Yabe T., Sanagi T. and Yamada H., The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders, Current Molecular Medicine 2010; 10 (3) . https://dx.doi.org/10.2174/156652410791065354
DOI https://dx.doi.org/10.2174/156652410791065354 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dimebon Attenuates the Aβ-Induced Mitochondrial Permeabilization
Current Alzheimer Research Ketamine: New Indications for an Old Drug
Current Drug Targets Subcellular Injuries in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets miRNAs in Alzheimer Disease – A Therapeutic Perspective
Current Alzheimer Research A Protective Role of Translocator Protein in Alzheimer’s Disease Brain
Current Alzheimer Research LHON: Mitochondrial Mutations and More
Current Genomics Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Effects of Anesthetics on Mitochondrial Signaling and Function
Current Drug Safety Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology 5-Adenosine Monophosphate-Activated Protein Kinase and the Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease
Letters in Drug Design & Discovery Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Pharmaceutical Strategies for Activating Sirtuins
Current Pharmaceutical Design Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Gene Therapy in the Management of Parkinson’s Disease: Potential of GDNF as a Promising Therapeutic Strategy
Current Gene Therapy Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
Current Pharmaceutical Design Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research